Technologies

WurQ combines wearable sensors, with deep learning and signal processing algorithms, to assess the amount, quality, and intensity of functional movements and strength training activities. This quantitative data enables feedback, guidance, and gamification at scale to improve users fitness routines and health.

StataDX licensed the eRapid portable electrochemical sensing technology to develop diagnostics for neurological, cardiovascular, and renal diseases with a first focus on building a point-of-care platform for difficult-to-detect neurological disorders.

Project 1985 is commercializing the Wyss Institute’s Pop-Up MEMS technology to quickly and cheaply develop tiny robotic tools for minimally invasive surgery.

Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.

Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized.

This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute.